Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. (LAB) pioneers precision tools for accelerating biomedical discoveries in proteomics and genomics. This dedicated news hub provides investors, researchers, and industry professionals with comprehensive updates on the company's advancements in mass cytometry, microfluidics, and high-throughput research solutions.
Access real-time press releases, earnings reports, and strategic announcements to stay informed about LAB's innovations in life sciences technology. Our curated collection includes updates on product launches, clinical research collaborations, and scientific milestones that shape the future of translational medicine.
Key content categories cover financial performance, technology partnerships, and regulatory developments, alongside insights into applications across oncology, immunology, and biomarker discovery. Each update is verified for accuracy and relevance, ensuring you receive authoritative information directly impacting biomedical research trends.
Bookmark this page for streamlined access to Standard BioTools' latest progress in developing automated, sample-efficient platforms trusted by leading academic institutions and pharmaceutical organizations worldwide.
Standard BioTools Inc. (Nasdaq:LAB) announced that President and CEO Michael Egholm, PhD, will present at the Cowen Health Care Conference on March 8, 2023, at 12:50 p.m. ET. The presentation will be available via live webcast on the Investor Relations page of the company’s website. Standard BioTools, previously Fluidigm Corporation, is committed to accelerating breakthroughs in human health through its advanced technologies, including mass cytometry and microfluidics. The company serves a wide range of clients in biomedical research, focusing on oncology, immunology, and other critical areas.
Standard BioTools Inc. (Nasdaq:LAB) announced the grant of equity awards under its 2022 Inducement Equity Incentive Plan, effective February 20, 2023, to incentivize four new employees. The awards encompass a total of 85,000 restricted stock units (RSUs), which will vest over a period, with 1/4th vesting on February 20, 2024, and the remainder vesting quarterly thereafter. This move is aligned with Nasdaq Listing Rule 5635(c)(4). The company continues its commitment to revolutionizing biomedical research through innovative technologies that enhance patient outcomes.
Standard BioTools reported fourth quarter 2022 GAAP revenues of $27.0 million, with core product and service revenues at $26.8 million, marking an 8.3% sequential growth. For the full year, GAAP revenues totaled $97.9 million, down from $130.6 million in 2021. The company expects flat to moderate growth for 2023's core revenues, impacted by a $5 million Genomics headwind. Operating expenses decreased 16% sequentially in Q4, with an anticipated 20% reduction in 2023 costs. Cash reserves at year-end stood at $165.8 million, providing a runway for positive free cash flow by 2024. Gross margins are projected to expand significantly by Q4 2023.
Standard BioTools Inc. (Nasdaq:LAB) has announced its plans to report its fourth quarter and full year 2022 financial results on February 14, 2023, after market close. A conference call and webcast will follow at 2:00 p.m. PT to discuss these results and the company's operational progress. Interested parties can listen through provided call-in numbers. The company is recognized for its innovative technologies aiding biomedical research and aims to enhance patient outcomes through its next-generation solutions.
Standard BioTools Inc. (Nasdaq: LAB) reported a 4%-9% sequential growth in core revenue, reaching $26 million to $27 million in Q4 2022, totaling approximately $94 million to $95 million for the year. The company is on track to achieve over 20% reduction in operating expenses (over $30 million), aiming for positive free cash flow by Q4 2024. With $165 million in cash reserves, Standard BioTools is executing its inorganic strategy and targeting a 65%-68% non-GAAP gross margin by end of 2023.
Standard BioTools Inc. has appointed Betsy Jensen as their new Chief Human Resources Officer, enhancing their management team. This strategic move is aimed at supporting the company's ambitious growth and profitability goals. Jensen, with significant experience at Danaher and Gibraltar, is expected to drive talent acquisition and development, vital for the firm’s success. CEO Michael Egholm emphasized the importance of team culture and leadership in achieving organizational objectives. This appointment reflects Standard BioTools’ commitment to strengthening leadership amid industry competition.
Standard BioTools (Nasdaq:LAB) has authorized a stock buyback of up to $20 million through December 31, 2023. This initiative aims to utilize cash on hand effectively, reflecting confidence in the company’s valuation and alignment with its strategic goals for revenue growth and profitability. The board believes the buyback will enhance shareholder value, although it may be suspended or discontinued at any time. Forward-looking statements indicate potential risks affecting the company's performance and cash balance.
Standard BioTools Inc. (Nasdaq:LAB) announced the grant of equity awards on November 20, 2022, under its 2022 Inducement Equity Incentive Plan to ten new employees. The awards comprise 235,200 restricted stock units (RSUs), with 25% vesting on November 20, 2023, and the remainder vesting quarterly thereafter. This move complies with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent. Standard BioTools focuses on providing innovative technologies for biomedical research, significantly impacting human health.
Standard BioTools (LAB) reported a strong third quarter, with core product and services revenue rising by 30% sequentially to $24.8 million. The company has initiated a restructuring program, enhancing operating margin by 600 to 800 basis points, equivalent to $8.0 million annually. They aim for a 65-68% non-GAAP gross margin by year-end 2023. Cash reserves stand at $185.2 million as of September 30, 2022, and they project achieving positive free cash flow by the end of 2024.
Standard BioTools has announced a collaboration with Visiopharm to enhance its Imaging Mass Cytometry (IMC) systems. The partnership integrates Visiopharm’s Phenoplex™ software with Standard BioTools' Hyperion™ and Hyperion+™ systems to optimize image processing and spatial pathology analysis. This collaboration aims to streamline workflows, allowing researchers to obtain more detailed biological data efficiently. The integration of AI technology is expected to accelerate insights into tumor microenvironments, improving research outcomes in healthcare.
